Developing better methods to detect DNA changes for early lung cancer detection
Core - Biomarker Development Laboratory (BDL)
This study is working on new ways to find early signs of lung cancer by looking for specific changes in DNA found in blood samples, which could help doctors tell if someone has lung cancer or another type of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10902050 on NIH RePORTER |
What this research studies
This research focuses on creating advanced techniques to identify DNA methylation changes that can signal the early presence of lung cancer. A team of experts will work on developing panels that can detect circulating tumor DNA (ctDNA) in blood plasma, helping to pinpoint whether this DNA comes from lung cancer or other cancers. By using high-quality biospecimens, the project aims to enhance the sensitivity and specificity of these detection methods, ultimately leading to improved diagnostic capabilities for lung cancer. The findings will be standardized and tested to ensure they meet clinical laboratory standards.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for lung cancer, such as smokers or those with a family history of the disease.
Not a fit: Patients who do not have lung cancer or are not at risk for developing lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of lung cancer, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using DNA methylation markers for cancer detection, indicating a potential for success in this approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Herman, James G. — University of Pittsburgh at Pittsburgh
- Study coordinator: Herman, James G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.